Europe Veterinary Healthcare Market Size, Share & Forecast, By Product Type, Animal Type & End User, 2026-2031

The Europe Veterinary Healthcare Market is valued at USD 16,920 million in 2025 under a scope covering veterinary therapeutics and diagnostics for companion animals and livestock. Therapeutics account for 61.88% of revenue, while dogs and cats represent 46.10% of market demand. Hospitals and clinics remain the principal purchasing setting at 54.85%. The market therefore combines a large recurring pharmaceutical pool with a faster-expanding diagnostic opportunity supported by pet ownership, preventive medicine, chronic-care treatment and livestock disease management.

The market is projected to reach USD 24,400 million by 2031, representing a 6.29% CAGR from the 2025 base. Expansion should be supported by companion-animal healthcare intensity, preventive biologics, specialized chronic-care products and increased diagnostic utilization. Diagnostics are expected to grow faster than the overall market at 7.18% CAGR, while point-of-care testing is forecast at 7.62%. This means the incremental revenue pool should be more technology-intensive than the installed market, even as established therapeutic categories remain the largest source of absolute revenue.

The clearest profit-pool shift is toward diagnostics, point-of-care workflows and advanced specialty therapeutics. Diagnostics are forecast to expand at 7.18% CAGR through 2031, while point-of-care settings are projected at 7.62%. These categories can generate recurring revenue from consumables, assays, instruments, software and follow-on treatment decisions. Traditional therapeutics will remain dominant, but their share is expected to gradually decline as diagnostic intensity rises. Companies integrating disease detection, clinical decision support and targeted treatment can potentially capture more revenue per veterinary episode than suppliers focused on standalone products.

The key structural risks are veterinary workforce constraints, antimicrobial portfolio transition and shrinking livestock populations in selected species. European veterinary antibiotic sales declined 53% between 2011 and 2022, while 2024 EU bovine numbers fell 2.8% year-on-year and pig numbers declined 0.5%. Workforce shortages add an execution constraint because labor availability determines clinic throughput and farm-service capacity. Suppliers therefore cannot rely solely on unit-volume expansion; they require prevention-led portfolios, labor-efficient diagnostics and higher value per treated animal to sustain revenue growth in mature categories.

Germany is the most strategically important national market, representing approximately 40.85% of European veterinary healthcare revenue in 2025 under the current market framework. Its leadership reflects substantial companion-animal expenditure, a developed veterinary system and a strong pharmaceutical innovation base. The United Kingdom is also strategically relevant because it is forecast to expand faster, at approximately 7.55% CAGR through 2031. France, Italy and Spain provide additional scale and diversification. National strategies should therefore balance Germany's absolute revenue opportunity against faster incremental growth in selected peer markets.

The strongest long-term demand foundation is the combination of companion-animal ownership and persistent infectious-disease management requirements. Europe has approximately 140 million pet-owning households, equal to 49% of households, supporting recurring vaccination, parasite control, diagnostics and chronic-care spending. Production-animal demand remains strategically important because Europe reported 406 domestic-bird HPAI outbreaks and 2,108 wild-bird detections across 32 countries between late November 2025 and late February 2026. Together, these demand pools create recurring requirements across both consumer-funded and agricultural veterinary healthcare.